Replies to post #170019 on Anavex Life Sciences Corp (AVXL)

[OFP]

Well DZP was, as per the CTAD 18 presentation, part of KEM analysis without being flagged as significant.

This is an important point but I'm not sure you see the logic of it. If DZP blocks receptor access this would be strong evidence of lack of an effect.

We just don't know if it was because only 1 patient was still on DZP

There were 21 patients included and 80% or more of original patients were on DZP (I forget the exact number) so it is not possible that only 1 patient on DZP was included in the recent analyses.

But, yes I guess you could ask Anavex if you really want to know.

I am interested for scientific/peripheral reasons. What I don't get is why people with money on the table are not more interested.